EN DE
Watch Pyridam Farma Tbk for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Pyridam Farma Tbk (PYFA) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Pyridam Farma Tbk stock IDR 123, price IDR 120, upside +2.1%, quality 22 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare ID · ISIN ID1000075609

PF Pyridam Farma Tbk logo Thin data Nov 10, 2026

Pyridam Farma Tbk

PYFA · JK
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Last quarter vs. a year ago: revenue +22%, profit +60%.
Fair value 122.57 IDR · Fairly valued
Expensive Growth (revenue 5y +58.3 %/yr in IDR)
Quality 22/100
Loss-making · -11.5% net margin (TTM)
High debt
Negative free cash flow
Trails peers (3/10)
Narrow moat 13/100 · thin data
Thin data
Estimate
Watch Pyridam Farma Tbk for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

1,400 IDR 87.00 IDR Fair Value 122.57 IDR Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 87.00 IDR – 1,400 IDR · fair‑value band 91.93 IDR – 153.22 IDR · the 120.00 IDR price screens below the 122.57 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Pyridam Farma Tbk in your weekly email

Every Wednesday you see whether Pyridam Farma Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PT Pyridam Farma Tbk engages in the pharmaceutical business in Australia, Indonesia, Philippines, Singapore, and India. The company operates through two segments, Pharmaceutical Products, Esthetic and Toll Manufacturing Services; and Medical Equipment segments.

Show moreShow less

It supplies medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR - extraction kit and extractor machine, speciment bag, sterile container, PCR machine- Gentier 48, and tube stopper.

The company also provides skin care and beauty products; medical support products; and other consumer health products in the form of syrups, tablets, and capsules; sterile and injection; and sanitizers and antiseptics.

In addition, it offers antiseptic solutions, betadine antiseptic skin cleansers, Betadine Vaginal Douche, Cold defense nasal and throat sprays, feminine hygiene, Guardix SG, Mouthwash and Gargle, Salep antiseptic products.

PT Pyridam Farma Tbk was founded in 1976 and is headquartered in Jakarta Selatan, Indonesia. PT Pyridam Farma Tbk operates as a subsidiary of Rejuve Global Investment Pte. Ltd.

Stock analysis

Pyridam Farma Tbk (PYFA) currently trades at 120.00 IDR, while our estimate is 122.57 IDR, so the stock looks roughly fairly valued today (gap 2.1%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 91.93 IDR (bear) to 153.22 IDR (bull), the price of 120.00 IDR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Pyridam Farma Tbk reported revenue of 2.8T IDR in FY2025 versus 631B IDR in FY2021, a compound +44.6%/yr. Reported net income was −380B IDR in FY2025.

Key figures

Market cap 1.3T IDR (≈ $74.9M) Micro · P/S ratio 0.53 · EPS (TTM) −29.56 IDR · Net margin −11.5% · Return on equity −39.3% · Return on assets (EBIT) 5.0% (5-year average) · Operating margin −0.2% · Revenue (TTM) 3.0T IDR.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).

What moves the price

The share trades about 80% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 2%, PYFA screens cheaper than that median.

Fair Value

Bear 91.93 IDR Fair Value 122.57 IDR Bull 153.22 IDR
Price 120.00 IDR · Upside +2.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 22/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 68
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 2
Debt, balance sheet and risk of trouble
Investment 28
Does it invest with discipline instead of growing at any price?
Low Volatility 38
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+43.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.3%
Start year 2020 (pandemic). Over 10 years: +28.9% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.6% (2020) → −5.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch PYFA, get fair value alerts →

Compare Pyridam Farma Tbk with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside +2.1% · Above median
Profitability
Return on assets −5.6% · Bottom 25%
Net margin (12 months) −11.5% · Bottom 25%
Operating margin (12 months) −0.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 21.6% · Top 25%
Balance sheet
Debt / equity 4.25× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.76× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 0.45× · Cheapest 25%
EV/EBITDA 54.4× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)36 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs PYFA
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs PYFA
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs PYFA
Haleon plc HLN $9.06 $8.62 −5% vs PYFA
Merck KGaA MRK €149.35 €109.18 −27% vs PYFA
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs PYFA
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs PYFA
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs PYFA
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs PYFA
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs PYFA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pyridam Farma Tbk: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Pyridam Farma Tbk Fair Value". https://www.fairvalue-calculator.com/stock/PYFA

Frequently asked questions

Is Pyridam Farma Tbk (PYFA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 122.57 IDR versus a price of 120.00 IDR, about +2% upside (fairly valued).
What is the fair value of PYFA?
Our estimate for Pyridam Farma Tbk is 122.57 IDR (as of Nov 10, 2026), built from audited fundamentals. The current price: 120.00 IDR.
What is the quality score of PYFA?
Pyridam Farma Tbk has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pyridam Farma Tbk (PYFA)?
Our calculated price target is the estimate of 122.57 IDR (as of Nov 10, 2026). Cautious scenario 91.93 IDR, optimistic scenario 153.22 IDR. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Pyridam Farma Tbk stock forecast for 2026?
Our estimate puts fair value at 122.57 IDR, about +2% upside versus a price of 120.00 IDR (fairly valued). Cautious scenario 91.93 IDR, optimistic scenario 153.22 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Pyridam Farma Tbk (PYFA)?
Pyridam Farma Tbk reported trailing-twelve-month revenue of about 3.0T IDR (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Pyridam Farma Tbk (PYFA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pyridam Farma Tbk it is 122.57 IDR per share (as of Nov 10, 2026), against a price of 120.00 IDR.
Is Pyridam Farma Tbk stock overvalued or undervalued in 2026?
As of Nov 10, 2026, PYFA trades below its calculated fair value: price 120.00 IDR, fair value 122.57 IDR, a gap of about +2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PYFA?
No. The price is what the market pays today (120.00 IDR); the fair value is what the company's own numbers justify (122.57 IDR). For Pyridam Farma Tbk the two are 2.57 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Pyridam Farma Tbk worth?
The market values Pyridam Farma Tbk at about 1.3T IDR (market capitalisation, as of Nov 10, 2026). Per share that is 120.00 IDR; our models calculate a fair value of 122.57 IDR per share.
What do the bullish and bearish scenarios say about PYFA?
Our models span a range for Pyridam Farma Tbk: cautious scenario 91.93 IDR, base 122.57 IDR, optimistic 153.22 IDR per share (as of Nov 10, 2026, price 120.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pyridam Farma Tbk (PYFA)?
Balance-sheet figures for Pyridam Farma Tbk (as of Nov 10, 2026): return on equity −39.3%, debt of 4.25 per unit of equity. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is PYFA from its 52-week high?
Pyridam Farma Tbk trades at 120.00 IDR, about 80% below its 52-week high of 595.00 IDR and 11% above the low of 108.00 IDR (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 122.57 IDR is for.
Which stocks are comparable to Pyridam Farma Tbk?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pyridam Farma Tbk stock attractive at the current price?
The data as of Nov 10, 2026: price 120.00 IDR, calculated fair value 122.57 IDR (+2%), Quality Score 22/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Pyridam Farma Tbk currently trades 2% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pyridam Farma Tbk (PYFA)?
The closing price on Nov 10, 2026 was 120.00 IDR. Our estimate is 122.57 IDR, about +2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pyridam Farma Tbk right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Pyridam Farma Tbk

How large is the market capitalisation of Pyridam Farma Tbk (PYFA)?
The market capitalisation of Pyridam Farma Tbk is 1.3T IDR (≈ $74.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pyridam Farma Tbk (PYFA)?
The price-to-sales ratio of Pyridam Farma Tbk is 0.53 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pyridam Farma Tbk (PYFA)?
Earnings per share at Pyridam Farma Tbk are −29.56 IDR. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pyridam Farma Tbk (PYFA)?
The net margin of Pyridam Farma Tbk is −11.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pyridam Farma Tbk (PYFA)?
The return on equity (ROE) of Pyridam Farma Tbk is −39.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pyridam Farma Tbk (PYFA)?
On an EBIT basis the return on assets of Pyridam Farma Tbk is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pyridam Farma Tbk (PYFA)?
The operating margin of Pyridam Farma Tbk is −0.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pyridam Farma Tbk (PYFA)?
Revenue at Pyridam Farma Tbk is growing +21.6% versus a year earlier (3y avg +56.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pyridam Farma Tbk (PYFA)?
Earnings per share at Pyridam Farma Tbk are growing +59.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Pyridam Farma Tbk (PYFA) generate?
The free cash flow of Pyridam Farma Tbk is −504B IDR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pyridam Farma Tbk (PYFA) carry?
The net debt of Pyridam Farma Tbk is 4.7T IDR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pyridam Farma Tbk in the live analysis

One click puts Pyridam Farma Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.